date,title,source
Oct-18-18,"Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-22-18,REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors,PR Newswire
Oct-26-18,REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting,PR Newswire
Oct-29-18,ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?,Zacks
Oct-31-18,REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights,PR Newswire
Nov-05-18,REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector,PR Newswire
Nov-06-18,REGENXBIO to Present at Upcoming Investor Conferences,PR Newswire
Nov-07-18,Regenxbio: 3Q Earnings Snapshot,Associated Press
Nov-07-18,This Rockville biotech is expanding to a new HQ. Here are the details.,American City Business Journals
Nov-07-18,REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II,PR Newswire
Nov-07-18,"Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facility",PR Newswire
Nov-12-18,"Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-13-18,Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Nov-14-18,FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease,PR Newswire
Nov-26-18,Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,Business Wire
Nov-26-18,REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,PR Newswire
Dec-04-18,"This Rockville biotech is getting some help from Maryland, MoCo for its new HQ",American City Business Journals
Dec-12-18,Is Regenxbio Inc (RGNX) A Good Stock To Buy?,Insider Monkey
Jan-03-19,REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update,PR Newswire
Jan-04-19,REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-29-19,Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Jan-31-19,REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease,PR Newswire
Feb-04-19,"Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies  Emerging Consolidated Expectations, Analyst Ratings",GlobeNewswire
Feb-14-19,REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists,PR Newswire
Feb-20-19,REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights,PR Newswire
Feb-26-19,5 Gene Therapy Stocks to Enrich Your Portfolio,Zacks
Feb-27-19,Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript,Motley Fool
Feb-27-19,REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights,PR Newswire
Feb-27-19,"The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure",Zacks
Feb-28-19,Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT,Thomson Reuters StreetEvents
Mar-01-19,Why Big Pharma Is Diving Into Gene Therapy,Barrons.com
Mar-04-19,3 Top Small-Cap Stocks to Buy Right Now,Motley Fool
Mar-05-19,REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher,Zacks
Mar-06-19,REGENXBIO to Participate in Upcoming Investor Conferences,PR Newswire
Mar-08-19,Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?,Motley Fool
Mar-26-19,"New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex  Consolidated Revenues, Company Growth, and Expectations for 2019",GlobeNewswire
Apr-03-19,3 Small-Cap Biotech Stocks to Watch Now,Motley Fool
Apr-08-19,4 Gene Therapy Players Likely to Become Buyout Targets in 2019,Zacks
Apr-15-19,REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting,PR Newswire
Apr-17-19,REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer,PR Newswire
Apr-22-19,A Second Baby Died In A Gene Therapy Study  Slugging This Biotech Stock,Investor's Business Daily
Apr-30-19,REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights,PR Newswire
May-02-19,Is Regenxbio Inc (RGNX) A Good Stock To Buy?,Insider Monkey
May-07-19,Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript,Motley Fool
May-07-19,Regenxbio: 1Q Earnings Snapshot,Associated Press
May-07-19,REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD,PR Newswire
May-08-19,REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference,PR Newswire
May-08-19,Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT,Thomson Reuters StreetEvents
May-15-19,REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies,PR Newswire
May-24-19,Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio,Motley Fool
May-28-19,FDA approves most expensive gene therapy ever  and here is its connection to Penn,American City Business Journals
May-28-19,REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%,Zacks
